Risk prediction of in-stent restenosis among patients with coronary drug-eluting stents: current clinical approaches and challenges

References

• Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331:489–495.
   PubMed Web of Science ®Google Scholar
• Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med. 1994;331:496–501.
   PubMed Web of Science ®Google Scholar
• Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44–52.
   PubMed Web of Science ®Google Scholar
• Farb A, Weber DK, Kolodgie FD, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974–2980.
   PubMed Web of Science ®Google Scholar
• Teirstein PS, Massullo V, Jani S, et al. Two-year follow-up after catheter-based radiotherapy to inhibit coronary restenosis. Circulation. 1999;99:243–247.
   PubMed Web of Science ®Google Scholar
• Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103:192–195.
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323.
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780.
   PubMed Web of Science ®Google Scholar
• Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52:1134–1140.
   PubMed Web of Science ®Google Scholar
• Vink MA, Dirksen MT, Suttorp MJ, et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-eluting versus conventional stent in myocardial infarction with ST-segment elevation) trial. JACC Cardiovasc Interv. 2011;4:24–29.
   PubMed Web of Science ®Google Scholar
• Kimura T, Morimoto T, Natsuaki M, et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the randomized evaluation of Sirolimus-eluting versus Everolimus-eluting stent trial (RESET). Circulation. 2012;126:1225–1236.
   PubMed Web of Science ®Google Scholar
• Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202.
   PubMed Web of Science ®Google Scholar
• Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435–2441.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Guo Y, Samadashvili Z, et al. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Engl J Med. 2015;372:1213–1222.
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57:1314–1322.
   PubMed Web of Science ®Google Scholar
• Madhavan MV, Kirtane AJ, Redfors B, et al. Stent-related adverse events >1 year after percutaneous coronary intervention. J Am Coll Cardiol. 2020;75:590–604.
   PubMedGoogle Scholar
• Kuntz RE, Baim DS. Defining coronary restenosis. Newer clinical and angiographic paradigms. Circulation. 1993;88:1310–1323.
   PubMed Web of Science ®Google Scholar
• Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol. 1974;33:87–94.
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–2351.
   PubMed Web of Science ®Google Scholar
• Dangas GD, Claessen BE, Caixeta A, et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56:1897–1907.
   PubMed Web of Science ®Google Scholar
• Briguori C, Anzuini A, Airoldi F, et al. Intravascular ultrasound criteria for the assessment of the functional significance of intermediate coronary artery stenoses and comparison with fractional flow reserve. Am J Cardiol. 2001;87:136–141.
   PubMed Web of Science ®Google Scholar
• Jasti V, Ivan E, Yalamanchili V, et al. Correlations between fractional flow reserve and intravascular ultrasound in patients with an ambiguous left main coronary artery stenosis. Circulation. 2004;110:2831–2836.
   PubMed Web of Science ®Google Scholar
• Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267–274.
   PubMed Web of Science ®Google Scholar
• Schwartz RS, Holmes DR Jr., Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992;20:1284–1293.
   PubMed Web of Science ®Google Scholar
• Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22:1769–1776.
   PubMed Web of Science ®Google Scholar
• Chung IM, Gold HK, Schwartz SM, et al. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol. 2002;40:2072–2081.
   PubMed Web of Science ®Google Scholar
• Carter AJ, Farb A, Gould KE, et al. The degree of neointimal formation after stent placement in atherosclerotic rabbit iliac arteries is dependent on the underlying plaque. Cardiovasc Pathol. 1999;8:73–80.
   PubMed Web of Science ®Google Scholar
• Carter AJ, Laird JR, Farb A, et al. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol. 1994;24:1398–1405.
   PubMed Web of Science ®Google Scholar
• Kimura T, Yokoi H, Nakagawa Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med. 1996;334:561–566.
   PubMed Web of Science ®Google Scholar
• Kuroda N, Kobayashi Y, Nameki M, et al. Intimal hyperplasia regression from 6 to 12 months after stenting. Am J Cardiol. 2002;89:869–872.
   PubMed Web of Science ®Google Scholar
• Nakano M, Otsuka F, Yahagi K, et al. Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics. Eur Heart J. 2013;34:3304–3313.
   PubMed Web of Science ®Google Scholar
• Park DW, Hong MK, Mintz GS, et al. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late “catch-up” phenomenon from ASPECT Study. J Am Coll Cardiol. 2006;48:2432–2439.
   PubMed Web of Science ®Google Scholar
• Kang SJ, Park DW, Mintz GS, et al. Long-term vascular changes after drug-eluting stent implantation assessed by serial volumetric intravascular ultrasound analysis. Am J Cardiol. 2010;105:1402–1408.
   PubMed Web of Science ®Google Scholar
• Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36:2147–2159.
   PubMed Web of Science ®Google Scholar
• Mori H, Finn AV, Atkinson JB, et al. Calcified nodule: an early and late cause of In-Stent failure. JACC Cardiovasc Interv. 2016;9:15.
   Web of Science ®Google Scholar
• Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333–342.
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Nakano M, Otsuka F, et al. Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circ Cardiovasc Interv. 2011;4:38–46.
   PubMed Web of Science ®Google Scholar
• Otsuka F, Finn AV, Yazdani SK, et al. The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol. 2012;9:439–453.
   PubMed Web of Science ®Google Scholar
• Otsuka F, Pacheco E, Perkins LE, et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv. 2014;7:330–342.
   PubMed Web of Science ®Google Scholar
• Kukreja N, Onuma Y, Serruys PW. Xience V everolimus-eluting coronary stent. Expert Rev Med Devices. 2009;6:219–229.
   PubMed Web of Science ®Google Scholar
• Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201–209.
   PubMed Web of Science ®Google Scholar
• Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663–1674.
   PubMed Web of Science ®Google Scholar
• Jensen LO, Thayssen P, Hansen HS, et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian organization for randomized trials with clinical outcome IV (SORT OUT IV). Circulation. 2012;125:1246–1255.
   PubMed Web of Science ®Google Scholar
• Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393–1402.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125:2873–2891.
   PubMed Web of Science ®Google Scholar
• Otsuka F, Vorpahl M, Nakano M, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129:211–223.
   PubMed Web of Science ®Google Scholar
• Dejana E, Vestweber D. The role of VE-cadherin in vascular morphogenesis and permeability control. Prog Mol Biol Transl Sci. 2013;116:119–144.
   PubMed Web of Science ®Google Scholar
• Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci. 2008;121:2115–2122.
   PubMed Web of Science ®Google Scholar
• Habib A, Karmali V, Polavarapu R, et al. Sirolimus-FKBP12.6 impairs endothelial barrier function through protein kinase C-α activation and disruption of the p120-vascular endothelial cadherin interaction. Arterioscler Thromb Vasc Biol. 2013;33:2425–2431.
   PubMed Web of Science ®Google Scholar
• Harari E, Guo L, Smith SL, et al. Direct targeting of the mTOR (Mammalian target of Rapamycin) Kinase improves endothelial permeability in drug-eluting stents-brief report. Arterioscler Thromb Vasc Biol. 2018;38:2217–2224.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Serruys PW, Silber S, et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8:002230.
   PubMed Web of Science ®Google Scholar
• Bønaa KH, Mannsverk J, Wiseth R, et al. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016;375:1242–1252.
   PubMed Web of Science ®Google Scholar
• Moussa I, Stone G, Teirstein P, et al. TCT-117 the burden of restenosis after coronary stent implantation in the United States: temporal trends, clinical presentation, treatment strategies, and in-hospital outcomes. J Am Coll Cardiol. 2018;72:B50–B51.
   Web of Science ®Google Scholar
• Waldo SW, O’Donnell CI, Prouse A, et al. Incidence, procedural management, and clinical outcomes of coronary in-stent restenosis: insights from the National VA CART program. Catheter Cardiovasc Interv. 2018;91:425–433.
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231.
   PubMed Web of Science ®Google Scholar
• Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol. 2010;55:543–554.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136–146.
   PubMed Web of Science ®Google Scholar
• Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a prospective, randomized, multicenter trial to assess an everolimus-eluting coronary stent system [PROMUS element] for the treatment of up to two de Novo coronary artery lesions) trial. J Am Coll Cardiol. 2011;57:1700–1708.
   PubMed Web of Science ®Google Scholar
• Christiansen EH, Jensen LO, Thayssen P, et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet. 2013;381:661–669.
   PubMed Web of Science ®Google Scholar
• Saito S, Valdes-Chavarri M, Richardt G, et al. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical evaluation of new terumo drug-eluting coronary stent system in the treatment of patients with coronary artery disease) trial. Eur Heart J. 2014;35:2021–2031.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Mauri L, Koolen JJ, et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017;390:1843–1852.
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Meredith IT, Windecker S, et al. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II randomized trial. Circ Cardiovasc Interv. 2015;8:e002372.
   PubMed Web of Science ®Google Scholar
• Raungaard B, Jensen LO, Tilsted HH, et al. Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. Lancet. 2015;385:1527–1535. (Ref.122);
   PubMed Web of Science ®Google Scholar
• Zhai C, Cong H, Hou K, et al. Clinical outcome comparison of percutaneous coronary intervention and bypass surgery in diabetic patients with coronary artery disease: a meta-analysis of randomized controlled trials and observational studies. Diabetol Metab Syndr. 2019;11:110.
   PubMed Web of Science ®Google Scholar
• Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381:629–638.
   PubMed Web of Science ®Google Scholar
• Généreux P, Madhavan MV, Mintz GS, et al. Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing outcomes with revascularization and stents in Acute myocardial infarction) and ACUITY (Acute catheterization and urgent intervention triage strategy) TRIALS. J Am Coll Cardiol. 2014;63:1845–1854.
   PubMed Web of Science ®Google Scholar
• Choong Hou K, Sin Yoong Kong K, Kee Yi Shern T, et al. Impact of chronic kidney insufficiency on cardiovascular outcomes in patients that undergo coronary revascularization: a historical review. ASEAN Heart J. 2016;24:8.
   PubMedGoogle Scholar
• Gilbert J, Raboud J, Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care. 2004;27:990–994.
   PubMed Web of Science ®Google Scholar
• Qin SY, Zhou Y, Jiang HX, et al. The association of diabetes mellitus with clinical outcomes after coronary stenting: a meta-analysis. PLoS One. 2013;8:e72710.
   PubMedGoogle Scholar
• Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 1998;32:584–589.
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Waltenberger J, Rogers JH. Percutaneous coronary intervention in patients with diabetes: current concepts and future directions. J Diabetes Sci Technol. 2014;8:581–589.
   PubMedGoogle Scholar
• Zheng C, Kang J, Park KW, et al. The predictors of target lesion revascularization and rate of In-Stent restenosis in the second-generation drug-eluting stent era. J Interv Cardiol. 2019;2019:3270132.
   Web of Science ®Google Scholar
• Lee MS, David EM, Makkar RR, et al. Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation-fibrinolysis system. J Pathol. 2004;203:861–870.
   PubMed Web of Science ®Google Scholar
• Aronson D, Edelman ER. Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord. 2010;11:75–86.
   PubMed Web of Science ®Google Scholar
• Cai Q, Mukku VK, Ahmad M. Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr Cardiol Rev. 2013;9:331–339.
   PubMedGoogle Scholar
• Lee JM, Kang J, Lee E, et al. Chronic kidney disease in the second-generation drug-eluting stent era: pooled analysis of the Korean multicenter drug-eluting stent registry. JACC Cardiovasc Interv. 2016;9:2097–2109.
   PubMed Web of Science ®Google Scholar
• Weintraub WS, Kosinski AS, Brown CL 3rd, et al. Can restenosis after coronary angioplasty be predicted from clinical variables? J Am Coll Cardiol. 1993;21:6–14.
   PubMed Web of Science ®Google Scholar
• Brown RA, Williams M, Barker CM, et al. Sex-specific outcomes following revascularization with zotarolimus-eluting stents: comparison of angiographic and late-term clinical results. Catheter Cardiovasc Interv. 2010;76:804–813.
   PubMed Web of Science ®Google Scholar
• Rathore S, Terashima M, Katoh O, et al. Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: contemporary practice in real world patients. EuroInterv. 2009;5:349–354.
   PubMed Web of Science ®Google Scholar
• Singh M, Gersh BJ, McClelland RL, et al. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the prevention of restenosis with tranilast and its outcomes (PRESTO) trial. Circulation. 2004;109:2727–2731.
   PubMed Web of Science ®Google Scholar
• Agema WR, Monraats PS, Zwinderman AH, et al. Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. Eur Heart J. 2004;25:1163–1170.
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002;40:2082–2089.
   PubMed Web of Science ®Google Scholar
• Zhou S, Mu G, Wei S, et al. Associations between polymorphisms of endothelial nitric oxide synthase, matrix Metalloproteinase 3, Angiotensinogen, and Angiotensin II Type 1 receptor and risk of restenosis after percutaneous coronary intervention: a meta-analysis. Clin Ther. 2020;42:458–474.
   PubMed Web of Science ®Google Scholar
• Jukema JW, Verschuren JJ, Ahmed TA, et al. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol. 2011;9:53–62.
   PubMed Web of Science ®Google Scholar
• Yusuf RZ, Duan Z, Lamendola DE, et al. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003;3:1–19.
   PubMed Web of Science ®Google Scholar
• Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat. 2001;4:378–391.
   PubMed Web of Science ®Google Scholar
• Köster R, Vieluf D, Kiehn M, et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet. 2000;356:1895–1897.
   PubMed Web of Science ®Google Scholar
• Gong Z, Li M, Guo X, et al. Stent implantation in patients with metal allergy: a systemic review and meta-analysis. Coron Artery Dis. 2013;24:684–689.
   PubMed Web of Science ®Google Scholar
• Romero-Brufau S, Best PJ, Holmes DR Jr., et al. Outcomes after coronary stent implantation in patients with metal allergy. Circ Cardiovasc Interv. 2012;5:220–226.
   PubMed Web of Science ®Google Scholar
• Mori H, Kutys R, Romero M, et al. Metallic coronary stents: is there a relationship between stent fracture and hypersensitivity? JACC Cardiovasc Interv. 2017;10:1175–1177.
   PubMed Web of Science ®Google Scholar
• Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701–705.
   PubMed Web of Science ®Google Scholar
• Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the research on adverse drug events and reports (RADAR) project. J Am Coll Cardiol. 2006;47:175–181.
   PubMed Web of Science ®Google Scholar
• Genereux P, Madhavan MV, Mintz GS, et al. Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing outcomes with revascularization and stents in Acute myocardial infarction) and ACUITY (Acute catheterization and urgent intervention triage strategy) TRIALS. J Am Coll Cardiol. 2014;63:1845–1854.
   PubMed Web of Science ®Google Scholar
• Onuma Y, Tanimoto S, Ruygrok P, et al. Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study. Catheter Cardiovasc Interv. 2010;76:634–642.
   PubMed Web of Science ®Google Scholar
• LaDisa JF Jr., Olson LE, Douglas HA, et al. Alterations in regional vascular geometry produced by theoretical stent implantation influence distributions of wall shear stress: analysis of a curved coronary artery using 3D computational fluid dynamics modeling. Biomed Eng Online. 2006;5:5–40.
   Web of Science ®Google Scholar
• Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426–2434.
   PubMed Web of Science ®Google Scholar
• Torii S, Jinnouchi H, Sakamoto A, et al. Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: impact on healing. Eur Heart J. 2020;41:786–796.
   PubMed Web of Science ®Google Scholar
• Aoki J, Ikari Y. Cardiovascular disease in patients with end-stage renal disease on hemodialysis. Ann Vasc Dis. 2017;10:327–337.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab M, Baev R, Dieker P, et al. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions. Catheter Cardiovasc Interv. 2013;81:285–291.
   PubMed Web of Science ®Google Scholar
• Dardas P, Mezilis N, Ninios V, et al. The use of rotational atherectomy and drug-eluting stents in the treatment of heavily calcified coronary lesions. Hellenic J Cardiol. 2011;52:399–406.
   PubMed Web of Science ®Google Scholar
• Barbato E, Shlofmitz E, Milkas A, et al. State of the art: evolving concepts in the treatment of heavily calcified and undilatable coronary stenoses - from debulking to plaque modification, a 40-year-long journey. EuroIntervention. 2017;13:696–705.
   PubMed Web of Science ®Google Scholar
• Kini AS, Vengrenyuk Y, Pena J, et al. Optical coherence tomography assessment of the mechanistic effects of rotational and orbital atherectomy in severely calcified coronary lesions. Catheter Cardiovasc Interv. 2015;86:1024–1032.
   PubMed Web of Science ®Google Scholar
• Brinton TJ, Ali ZA, Hill JM, et al. Feasibility of shockwave coronary intravascular lithotripsy for the treatment of calcified coronary stenoses. Circulation. 2019;139:834–836.
   PubMed Web of Science ®Google Scholar
• Ali ZA, Nef H, Escaned J, et al. Safety and effectiveness of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses: the disrupt CAD II study. Circ Cardiovasc Interv. 2019;12:e008434.
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Hill JM, Ben-Yehuda O, et al. Evaluation of safety and efficacy of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses: design and rationale for the Disrupt CAD III trial. Am Heart J. 2020;225:10–18.
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–2130.
   PubMed Web of Science ®Google Scholar
• Behan MW, Holm NR, de Belder AJ, et al. Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the nordic bifurcation study and the British bifurcation coronary study. Eur Heart J. 2016;37:1923–1928.
   PubMed Web of Science ®Google Scholar
• Cornelissen A, Guo L, Sakamoto A, et al. Histopathologic and physiologic effect of bifurcation stenting: current status and future prospects. Expert Rev Med Devices. 2020;17:189–200.
   PubMed Web of Science ®Google Scholar
• Friedman MH, Deters OJ, Bargeron CB, et al. Shear-dependent thickening of the human arterial intima. Atherosclerosis. 1986;60:161–171.
   PubMed Web of Science ®Google Scholar
• Prosi M, Perktold K, Ding Z, et al. Influence of curvature dynamics on pulsatile coronary artery flow in a realistic bifurcation model. J Biomech. 2004;37:1767–1775.
   PubMed Web of Science ®Google Scholar
• Morbiducci U, Kok AM, Kwak BR, et al. Atherosclerosis at arterial bifurcations: evidence for the role of haemodynamics and geometry. Thromb Haemost. 2016;115:484–492.
   PubMed Web of Science ®Google Scholar
• Chiastra C, Gallo D, Tasso P, et al. Healthy and diseased coronary bifurcation geometries influence near-wall and intravascular flow: A computational exploration of the hemodynamic risk. J Biomech. 2017;58:79–88.
   PubMed Web of Science ®Google Scholar
• Walpola PL, Gotlieb AI, Cybulsky MI, et al. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress. Arterioscler Thromb Vasc Biol. 1995;15:2–10.
   PubMed Web of Science ®Google Scholar
• Bryan MT, Duckles H, Feng S, et al. Mechanoresponsive networks controlling vascular inflammation. Arterioscler Thromb Vasc Biol. 2014;34:2199–2205.
   PubMed Web of Science ®Google Scholar
• Chatzizisis YS, Jonas M, Coskun AU, et al. Prediction of the localization of high-risk coronary atherosclerotic plaques on the basis of low endothelial shear stress: an intravascular ultrasound and histopathology natural history study. Circulation. 2008;117:993–1002.
   PubMed Web of Science ®Google Scholar
• Grøttum P, Svindland A, Walløe L. Localization of atherosclerotic lesions in the bifurcation of the main left coronary artery. Atherosclerosis. 1983;47:55–62.
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Yazdani SK, Finn AV, et al. Pathological findings at bifurcation lesions: the impact of flow distribution on atherosclerosis and arterial healing after stent implantation. J Am Coll Cardiol. 2010;55:1679–1687.
   PubMed Web of Science ®Google Scholar
• LaDisa JF Jr., Guler I, Olson LE, et al. Three-dimensional computational fluid dynamics modeling of alterations in coronary wall shear stress produced by stent implantation. Ann Biomed Eng. 2003;31:972–980.
   PubMed Web of Science ®Google Scholar
• Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123:1400–1409.
   PubMed Web of Science ®Google Scholar
• Lassen JF, Holm NR, Banning A, et al. Percutaneous coronary intervention for coronary bifurcation disease: 11th consensus document from the European Bifurcation Club. EuroInterv. 2016;12:38–46.
   PubMed Web of Science ®Google Scholar
• Richter Y, Groothuis A, Seifert P, et al. Dynamic flow alterations dictate leukocyte adhesion and response to endovascular interventions. J Clin Invest. 2004;113:1607–1614.
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165.
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Catheter Cardiovasc Interv. 2013;82:7.
   Web of Science ®Google Scholar
• Katritsis DG, Siontis GC, Ioannidis JP. Double versus single stenting for coronary bifurcation lesions: a meta-analysis. Circ Cardiovasc Interv. 2009;2:409–415.
   PubMed Web of Science ®Google Scholar
• Song PS, Song YB, Lee JM, et al. Major predictors of long-term clinical outcomes after percutaneous coronary intervention for coronary bifurcation lesions with 2-stent strategy: patient-level analysis of the Korean bifurcation pooled cohorts. JACC Cardiovasc Interv. 2016;9:1879–1886.
   PubMed Web of Science ®Google Scholar
• Mori H, Torii S, Harari E, et al. Pathological mechanisms of left main stent failure. Int J Cardiol. 2018;263:9–16.
   PubMed Web of Science ®Google Scholar
• Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation. 2004;109:1244–1249.
   PubMed Web of Science ®Google Scholar
• Thuesen L, Kelbaek H, Kløvgaard L, et al. Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the stenting coronary arteries in non-stress/Benestent disease trial (SCANDSTENT). Am Heart J. 2006;152:1140–1145.
   PubMed Web of Science ®Google Scholar
• Lee JM, Hahn JY, Kang J, et al. Differential prognostic effect between first- and second-generation drug-eluting stents in coronary bifurcation lesions: patient-level analysis of the Korean bifurcation pooled cohorts. JACC Cardiovasc Interv. 2015;8:1318–1331.
   PubMed Web of Science ®Google Scholar
• Ohya M, Morimoto T, Kubo S, et al. Two-year outcomes and predictors of target lesion revascularization for non-left main coronary bifurcation lesions following two-stent strategy with 2nd-generation drug-eluting stents. Circ J. 2018;82:798–806.
   PubMed Web of Science ®Google Scholar
• Maehara A, Matsumura M, Ali ZA, et al. IVUS-guided versus OCT-guided coronary stent implantation: a critical appraisal. JACC Cardiovasc Imaging. 2017;10:1487–1503.
   PubMed Web of Science ®Google Scholar
• Ali ZA, Maehara A, Généreux P, et al. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial. Lancet. 2016;388:2618–2628.
   PubMed Web of Science ®Google Scholar
• Fujii K, Mintz GS, Kobayashi Y, et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation. 2004;109:1085–1088.
   PubMed Web of Science ®Google Scholar
• Song HG, Kang SJ, Ahn JM, et al. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation. Catheter Cardiovasc Interv. 2014;83:873–878.
   PubMed Web of Science ®Google Scholar
• Soeda T, Uemura S, Park SJ, et al. Incidence and clinical significance of poststent optical coherence tomography findings: one-year follow-up study from a multicenter registry. Circulation. 2015;132:1020–1029.
   PubMed Web of Science ®Google Scholar
• Prati F, Romagnoli E, Burzotta F, et al. Clinical impact of OCT findings during PCI: the CLI-OPCI II study. JACC Cardiovasc Imaging. 2015;8:1297–1305.
   PubMed Web of Science ®Google Scholar
• Leong DP, Dundon BK, Puri R, et al. Very late stent fracture associated with a sirolimus-eluting stent. Heart Lung Circ. 2008;17:426–428.
   PubMed Web of Science ®Google Scholar
• Shite J, Matsumoto D, Yokoyama M. Sirolimus-eluting stent fracture with thrombus, visualization by optical coherence tomography. Eur Heart J. 2006;27:24.
   Web of Science ®Google Scholar
• Chakravarty T, White AJ, Buch M, et al. Meta-analysis of incidence, clinical characteristics and implications of stent fracture. Am J Cardiol. 2010;106:1075–1080.
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Finn AV, Vorpahl M, et al. Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. J Am Coll Cardiol. 2009;54:1924–1931.
   PubMed Web of Science ®Google Scholar
• Kuramitsu S, Iwabuchi M, Haraguchi T, et al. Incidence and clinical impact of stent fracture after everolimus-eluting stent implantation. Circ Cardiovasc Interv. 2012;5:663–671.
   PubMed Web of Science ®Google Scholar
• Kuramitsu S, Hiromasa T, Enomoto S, et al. Incidence and clinical impact of stent fracture after PROMUS element platinum chromium everolimus-eluting stent implantation. JACC Cardiovasc Interv. 2015;8:1180–1188.
   PubMed Web of Science ®Google Scholar
• Sakamoto A, Torii S, Jinnouchi H, et al. Histopathologic and physiologic effect of overlapping vs single coronary stents: impact of stent evolution. Expert Rev Med Devices. 2018;15:665–682.
   PubMed Web of Science ®Google Scholar
• Ellis SG, Savage M, Fischman D, et al. Restenosis after placement of Palmaz-Schatz stents in native coronary arteries. Initial results of a multicenter experience. Circulation. 1992;86:1836–1844.
   PubMed Web of Science ®Google Scholar
• Kastrati A, Elezi S, Dirschinger J, et al. Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol. 1999;83:1617–1622.
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Wang H, Popma JJ, et al. Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J Am Coll Cardiol. 2006;48:21–31.
   PubMed Web of Science ®Google Scholar
• Räber L, Jüni P, Löffel L, et al. Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation. J Am Coll Cardiol. 2010;55:1178–1188.
   PubMed Web of Science ®Google Scholar
• Wilson GJ, Nakazawa G, Schwartz RS, et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation. 2009;120:141–149.
   PubMed Web of Science ®Google Scholar
• Kitabata H, Loh JP, Pendyala LK, et al. Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents. Am J Cardiol. 2013;112:1093–1098.
   PubMed Web of Science ®Google Scholar
• O’Sullivan CJ, Stefanini GG, Räber L, et al. Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents. EuroInterv. 2014;9:1076–1084.
   PubMed Web of Science ®Google Scholar
• Ortega-Paz L, Brugaletta S, Giacchi G, et al. Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: insights from the five-year follow-up of the EXAMINATION trial. EuroIntervention. 2017;13:e557–e563.
   PubMed Web of Science ®Google Scholar
• Farooq V, Vranckx P, Mauri L, et al. Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE program. Heart. 2013;99:626–633.
   PubMed Web of Science ®Google Scholar
• Park SH, Rha SW, Shin WY, et al. Real-world comparison of angiographic and 2-year clinical outcomes between first and second generation drug-eluting stents in patients received overlapping stents. Eur Heart J. 2013;34(supp_1):P3032.
   Web of Science ®Google Scholar
• Ota H, Mahmoudi M, Kitabata H, et al. Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis. Cardiovasc Revasc Med. 2015;16:84–89.
   PubMed Web of Science ®Google Scholar
• Maluenda G, Ben-Dor I, Gaglia MA Jr., et al. Clinical outcomes and treatment after drug-eluting stent failure: the absence of traditional risk factors for in-stent restenosis. Circ Cardiovasc Interv. 2012;5:12–19.
   PubMed Web of Science ®Google Scholar
• Ko YG, Kim JS, Kim BK, et al. Efficacy of drug-eluting stents for treating in-stent restenosis of drug-eluting stents (from the Korean DES ISR multicenter registry study [KISS]). Am J Cardiol. 2012;109:607–613.
   PubMed Web of Science ®Google Scholar
• Kubo S, Kadota K, Otsuru S, et al. Optimal treatment of recurrent restenosis lesions after drug-eluting stent implantation for in-stent restenosis lesions. EuroInterv. 2013;9:788–796.
   PubMed Web of Science ®Google Scholar
• Palmerini T, Della Riva D, Biondi-Zoccai G, et al. Mortality following nonemergent, uncomplicated target lesion revascularization after percutaneous coronary intervention: an individual patient data pooled analysis of 21 randomized trials and 32,524 patients. JACC Cardiovasc Interv. 2018;11:892–902.
   PubMed Web of Science ®Google Scholar
• Alfonso F, Byrne RA, Rivero F, et al. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63:2659–2673.
   PubMed Web of Science ®Google Scholar
• Siontis GC, Stefanini GG, Mavridis D, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet. 2015;386:655–664.
   PubMed Web of Science ®Google Scholar
• Giacoppo D, Alfonso F, Xu B, et al. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). Eur Heart J. 2020;41:3715–3728.
   Web of Science ®Google Scholar
• Giacoppo D, Alfonso F, Xu B, et al. Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis. J Am Coll Cardiol. 2020;75:2664–2678.
   PubMed Web of Science ®Google Scholar
• Katsanos K, Spiliopoulos S, Kitrou P, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.
   PubMed Web of Science ®Google Scholar
• Schneider PA, Laird JR, Doros G, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis. J Am Coll Cardiol. 2019;73:2550-2563.
   Web of Science ®Google Scholar
• Secemsky EA, Kundi H, Weinberg I, et al. Association of survival with Femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol. 2019;4:332-340.
   Web of Science ®Google Scholar
• Administration USFD. Treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality – letter to health care providers. 2019 [cited 2020 Jul 1]. available at: https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm633614.htm
   Google Scholar
• Rocha-Singh KJ, Duval S, Jaff MR, et al. Mortality and Paclitaxel-coated devices: an individual patient data meta-analysis. Circulation. 2020;141:1859–1869.
   PubMed Web of Science ®Google Scholar
• Vom Dahl J, Dietz U, Haager PK, et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). Circulation. 2002;105:583–588.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Kini A, Mehran R, et al. Randomized trial of rotational atherectomy versus balloon angioplasty for diffuse In-stent restenosis (ROSTER). Am Heart J. 2004;147:16–22.
   PubMed Web of Science ®Google Scholar
• Mehran R, Mintz GS, Satler LF, et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty: mechanisms and results compared with PTCA alone. Circulation. 1997;96:2183–2189.
   PubMed Web of Science ®Google Scholar
• Radke PW, Kaiser A, Frost C, et al. Outcome after treatment of coronary in-stent restenosis; results from a systematic review using meta-analysis techniques. Eur Heart J. 2003;24:266–273.
   PubMed Web of Science ®Google Scholar
• Megaly M, Glogoza M, Xenogiannis I, et al. Outcomes of intravascular brachytherapy for recurrent drug-eluting in-stent restenosis. Catheter Cardiovasc Interv. 2020;https://doi.org/10.1002/ccd.28716.
   Google Scholar